

ANI Pharmaceuticals, Inc.
Table 1: US GAAP Income Statement
(unaudited)

	Three months ended September 30,		Nine months ended September 30,	
	2013	2012	2013	2012
Net Revenues	\$ 7,836,222	\$ 5,036,024	\$ 19,549,670	\$ 15,049,619
Operating Expenses				
Cost of sales (excl. depreciation and amortization)	2,629,119	2,321,773	7,066,195	6,292,377
Salaries and benefits	1,729,066	1,291,667	8,699,638	3,516,427
Freight	81,416	80,622	224,189	242,814
Research and development	453,897	148,650	1,187,461	636,726
Selling, general and administrative	1,750,734	1,256,754	4,261,182	2,961,649
Depreciation and amortization	381,699	143,959	672,828	425,238
Total Operating Expenses	7,025,931	5,243,425	22,111,493	14,075,231
Operating Income/(Loss) from Continuing Operations	810,291	(207,401)	(2,561,823)	974,388
Other Income/(Expense)				
Interest expense	-	(81,225)	(466,902)	(1,239,137)
Other income/(expense)	147,563	(91,205)	(336,393)	(190,605)
Net Income/(Loss) from Continuing Operations Before Income Tax Benefit	957,854	(379,831)	(3,365,118)	(455,354)
Income tax benefit	82,852	866	82,852	36,327
Net Income/(Loss) from Continuing Operations	1,040,706	(378,965)	(3,282,266)	(419,027)
Discontinued Operation				
Gain on discontinued operation, net of tax	150,337	1,617	150,337	67,793
Net Income/(Loss)	\$ 1,191,043	\$ (377,348)	\$ (3,131,929)	\$ (351,234)
Basic and Diluted Earnings (Loss) Per Share				
Continuing operations	\$ 0.11	\$ (1,295.82)	\$ (2.31)	\$ (4,689.38)
Discontinued operation	0.02	0.72	0.04	66.99
Basic and Diluted Earnings (Loss) Per Share	\$ 0.13	\$ (1,295.10)	\$ (2.27)	\$ (4,622.39)
Basic and Diluted Weighted-Average Shares Outstanding	9,480,206	2,243	3,578,178	1,012

ANI Pharmaceuticals, Inc.
Table 2: Adjusted EBITDA Calculation and US GAAP to Non-GAAP Reconciliation
(unaudited)

	Three months ended		Nine months ended	
	September 30,		September 30,	
	2013	2012	2013	2012
Operating Income/(Loss) from Continuing Operations	\$810,291	(\$207,401)	(\$2,561,823)	\$974,388
Add back				
Depreciation and amortization	381,699	143,959	672,828	425,238
Merger-related expenses, not already added back	<u>500,677</u>	<u>328,404</u>	<u>5,468,062</u>	<u>328,404</u>
Adjusted EBITDA	<u>1,692,667</u>	<u>264,962</u>	<u>3,579,067</u>	<u>1,728,030</u>

ANI Pharmaceuticals, Inc.
Table 3: Adjusted Net Income and EPS from Continuing Operations Calculation
and US GAAP to Non-GAAP Reconciliation
(unaudited)

	Three months ended September 30, 2013	
		<i>Per Share Amounts</i>
Net Income from Continuing Operations	\$ 1,040,706	\$ 0.11
Add back		
Merger-related expenses	500,677	0.05
Adjusted Net Income from Continuing Operations	\$ 1,541,383	\$ 0.16